![]() |
HIV Infection |
Free Subscription
11 AIDS |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO HIV Infection is free of charge.
Interest and disparities in awareness and uptake of doxyPEP among U.S. MSM living
with HIV.
AIDS. 2025 Mar 27. doi: 10.1097/QAD.0000000000004192.
PubMed
Abstract available
Deciphering HIV vaccine-induced Antibody response according to ethnicity.
AIDS. 2025 Mar 31. doi: 10.1097/QAD.0000000000004196.
PubMed
Abstract available
Systematic review of infodemiology studies using artificial intelligence: social
media posts on HIV pre-exposure prophylaxis.
AIDS. 2025 Mar 27. doi: 10.1097/QAD.0000000000004193.
PubMed
Abstract available
A promising prognostic model for patients with AIDS-related lymphoma in the cART
era.
AIDS. 2025 Apr 1. doi: 10.1097/QAD.0000000000004197.
PubMed
Abstract available
Dolutegravir plus lamivudine downregulates cellular stress responses versus
three-drug HIV Regimens.
AIDS. 2025 Apr 1. doi: 10.1097/QAD.0000000000004198.
PubMed
Abstract available
Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate
injectable for women living with HIV on efavirenz: a prospective cohort study.
AIDS. 2025 Apr 3. doi: 10.1097/QAD.0000000000004201.
PubMed
Abstract available
Provision of care for people with HIV migrating from Ukraine: preparing for a
long-term response.
AIDS. 2025;39:629-638.
PubMed
Abstract available
Racial disparities in cancer risk among MSM with HIV in the United States.
AIDS. 2025;39:728-736.
PubMed
Abstract available
A refusal to abandon HIV science.
AIDS. 2025;39:768-770.
PubMed
What happened with preexposure prophylaxis uptake among female sex workers in
Zimbabwe? Implications for future prevention programmes.
AIDS. 2025;39:771-773.
PubMed
Food insecurity and mental health outcomes among people living with HIV in West
Africa.
AIDS. 2025 Apr 3. doi: 10.1097/QAD.0000000000004200.
PubMed
Abstract available
Indicators for Increased Likelihood of Epidemic Kaposi Sarcoma Progression after
Antiretroviral Therapy Initiation.
AIDS Res Hum Retroviruses. 2025 Apr 3. doi: 10.1089/aid.2025.0007.
PubMed
Abstract available
In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs.
daily oral F/TDF reduced HIV incidence.
Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00552.
PubMed
Abstract available
Infectious Diseases: What You May Have Missed in 2024.
Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00925.
PubMed
Abstract available
The effect of pregnancy on the population pharmacokinetics of levofloxacin in
South Africans with rifampicin-resistant tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
PubMed
Abstract available
HIV in primary care: further considerations.
BMJ. 2025;389:r639.
PubMed
Trump watch: HIV/AIDS research sent into crisis, growing hostility to mRNA
vaccines, and more.
BMJ. 2025;388:r645.
PubMed
Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in
ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter
Prospective Cohort Study.
Clin Infect Dis. 2025 Mar 28:ciae645. doi: 10.1093.
PubMed
Abstract available
A Metabolic Health Framework to Interpret Weight Gain Studies in People With
Human Immunodeficiency Virus.
Clin Infect Dis. 2025 Mar 28:ciae646. doi: 10.1093.
PubMed
Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra
for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus
in East London, South Africa.
Clin Infect Dis. 2025 Apr 2:ciaf080. doi: 10.1093.
PubMed
Abstract available
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
Clin Infect Dis. 2025 Apr 3:ciaf161. doi: 10.1093.
PubMed
Abstract available
Real-world HIV RNA and antigen/antibody testing among people who use long-acting
injectable PrEP.
Clin Infect Dis. 2025 Apr 3:ciaf173. doi: 10.1093.
PubMed
Abstract available
Differences in mortality in hospitalized advanced HIV disease between
treatment-naive and treatment-discontinuing individuals: a comparative
retrospective study from Mexico City.
Clin Infect Dis. 2025 Apr 3:ciaf175. doi: 10.1093.
PubMed
Abstract available
Changes in the prevalence of non-AIDS conditions among hospitalized persons with
HIV in the United States and Canada, 2008-2018.
Clin Infect Dis. 2025 Apr 2:ciaf167. doi: 10.1093.
PubMed
Abstract available
Rethinking HIV treatment: How non-integrase strand regimens may hold the key to
better immune health.
HIV Med. 2025 Mar 28. doi: 10.1111/hiv.70020.
PubMed
Abstract available
Late diagnosis of HIV among Ukrainian refugees in the Czech Republic: A
retrospective, observational study.
HIV Med. 2025 Mar 29. doi: 10.1111/hiv.70021.
PubMed
Abstract available
Strategies for strengthening same-day ART initiation, tracing people living with
HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.
HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70022.
PubMed
Abstract available
Prevalence of late HIV diagnosis and its impact on mortality: A comprehensive
systematic review and meta-analysis.
HIV Med. 2025 Apr 3. doi: 10.1111/hiv.70023.
PubMed
Abstract available
Integrating People With Lived Experience of Carceral System Involvement Into
Research: Lessons Learned From Ending the HIV Epidemic Research Teams.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Language Justice in Implementation Science: Experiences Working With Latinxs to
End the HIV Epidemic.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Not a Monolith: Regional HIV Implementation Science Lessons With Latino/a/x
Populations.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Lessons Learned in Engaging Adolescents and Young Adults to End the US HIV
Epidemic.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Communities Started the End of the HIV Epidemic: Experiences With and
Recommendations for Conducting Community-Engaged HIV Implementation Research.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Implementation Science Methods, Challenges, and Associated Solutions:
Transportable Lessons Learned and Best Practices From the Second National Meeting
for Research and Community Collaboration Toward Ending the HIV Epidemic in the
United States.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Generating Evidence for Effective HIV Implementation at Scale: The Value and
Feasibility of a Network for Implementation Science in HIV.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Community Engagement to Empowerment: Emphasizing Relationships, Process,
Resources, and Context to Strengthen Community Engagement in EHE Research
Partnerships.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Improving Community-Engaged Implementation Science: Perspectives From "Ending the
HIV Epidemic" Supplement Award Cases in the United States.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Community-Engaged Research in HIV Implementation Science: Characterizing Academic
and Community Partnerships in the "Ending the HIV Epidemic" Supplement Awards.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Building the Road to End the HIV Epidemic Through Coordinating and
Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch
(CHESHIRE): Reflections and Directions.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Leveraging Implementation Science to End the HIV Epidemic in the United States:
Progress and Opportunities for Federal Agencies.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Progress and Priorities to End the HIV Epidemic by 2030: Combined Lessons From
120 US Implementation Research Projects.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Predictive models to identify individuals with HIV at risk of unsuppressed viral
load using routine public health data.
J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003670.
PubMed
Abstract available
Poor Sleep Quality is Associated with Frailty Among Women with and without HIV.
J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003668.
PubMed
Abstract available
Cost-Effectiveness of a Tailored Pain Self-Management Intervention Compared to
Enhanced Usual Care Among People with HIV and Chronic Pain: An Economic
Evaluation.
J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003671.
PubMed
Abstract available
HIV Incidence among People Who Inject Drugs, San Francisco, 2022.
J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003673.
PubMed
Abstract available
Fatty acid signatures in people with HIV: association with adverse pregnancy
outcomes and offspring anthropometrics.
J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003665.
PubMed
Abstract available
Low placental growth factor levels mid-gestation predict small for gestational
age in pregnant women with HIV.
J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003672.
PubMed
Abstract available
Factors associated with recent HIV infections among newly HIV diagnosed in
Rwanda.
J Acquir Immune Defic Syndr. 2025 Apr 2. doi: 10.1097/QAI.0000000000003669.
PubMed
Abstract available
Two Pilots of an Implementation Science Training Program for HIV Prevention and
Care Service Providers: Lessons Learned and Future Directions.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Developing Implementation Science Capacity Within Health Departments Located in
Ending the HIV Epidemic Priority Areas.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Implementation Science Approaches to Addressing the Social and Structural
Determinants of Health of Criminal-Legal Involved People Living With HIV to
Improve HIV Care Outcomes.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Defining Study Populations in HIV Prevention Implementation Science Studies: A
Case Comparison of 3 Ending the HIV Epidemic Projects.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Lessons Learned From Engaging Healthcare Providers in Research on Implementation
of HIV Preexposure Prophylaxis.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded
Clinics: Results From a Multisite Survey.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Innovations to Address Unmet Behavioral Health Needs in National Ending the HIV
Epidemic Priority Jurisdictions.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United
States: Expanding Access in Nontraditional Settings.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations
and Opportunities to Move Forward.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned
From 11 Ending the HIV Epidemic Jurisdictions.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day
PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite
Qualitative Study.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by
Improving the Reporting of Implementation Strategies.
J Acquir Immune Defic Syndr. 2025;98.
PubMed
Abstract available
Insights into protection against Mycobacterium tuberculosis infection: time to
officially confirm another phenotype?
J Clin Invest. 2025;135:e191423.
PubMed
Abstract available
Safety and implementation of phase 1 randomized GLA-SE-adjuvanted CH505TF gp120
HIV vaccine trial in newborns.
J Clin Invest. 2025 Apr 3:e186927. doi: 10.1172/JCI186927.
PubMed
Abstract available
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and
Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or
Zinlirvimab.
J Infect Dis. 2025 Apr 3:jiaf159. doi: 10.1093.
PubMed
Abstract available
Mitochondrial disorders after 12 months of HIV-1 preexposure prophylaxis based on
tenofovir disoproxil fumarate plus emtricitabine in healthy adults.
J Infect Dis. 2025 Apr 1:jiaf156. doi: 10.1093.
PubMed
Abstract available
The Burden of HPV Infections and HPV-Related Diseases Among People With HIV: A
Systematic Literature Review.
J Med Virol. 2025;97:e70274.
PubMed
Abstract available
No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With
Monkeypox Virus Clade IIb Infected Patients.
J Med Virol. 2025;97:e70320.
PubMed
Abstract available
Sudan's war and the burden of HIV: a call for urgent intervention.
Lancet. 2025 Mar 27:S0140-6736(25)00547-1. doi: 10.1016/S0140-6736(25)00547.
PubMed
The effect of pertussis vaccination in pregnancy on the immunogenicity of
acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a
single-centre, randomised, controlled, double-blind, phase 4 trial.
Lancet Infect Dis. 2025 Mar 25:S1473-3099(25)00072.
PubMed
Abstract available
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and
endocarditis.
Lancet Infect Dis. 2025;25:e253-e254.
PubMed
Working at Cross-PURPOSEs to Ending HIV.
N Engl J Med. 2025;392:1344-1345.
PubMed
Trump team guts AIDS-eradication programme and slashes HIV research grants.
Nature. 2025 Mar 31. doi: 10.1038/d41586-025-00969.
PubMed
PrEP knowledge and perceptions among women living in North Carolina public
housing communities.
PLoS One. 2025;20:e0320093.
PubMed
Abstract available
A randomized, controlled trial of a web-based tailored intervention to increase
human papillomavirus vaccination among people living with HIV/AIDS.
PLoS One. 2025;20:e0319646.
PubMed
Abstract available
Preferences and willingness for starting daily, on-demand, and long-acting
injectable HIV pre-exposure prophylaxis among transfeminine persons in the US,
2022-2023.
PLoS One. 2025;20:e0320961.
PubMed
Abstract available
Comparison of HIV prevention indicators among adolescent girls and young women in
DREAMS and non-DREAMS intervention districts in Uganda.
PLoS One. 2025;20:e0321277.
PubMed
Abstract available
Mortality, loss to follow-up and advanced HIV disease following virologic success
in West African HIV-2 patients.
PLoS One. 2025;20:e0317223.
PubMed
Abstract available
Prevalence of detectable viral load and its associated factors among adult
patients receiving ART in Choma District, Zambia.
PLoS One. 2025;20:e0320571.
PubMed
Abstract available
Prevalence and associated factors of chronic kidney disease among adults
receiving antiretroviral therapy at Hawassa University Comprehensive Specialized
Hospital.
PLoS One. 2025;20:e0320787.
PubMed
Abstract available
Intact HIV DNA decays in children with and without complete viral load
suppression.
PLoS Pathog. 2025;21:e1013003.
PubMed
Abstract available
DHX15 inhibits mouse APOBEC3 deamination.
PLoS Pathog. 2025;21:e1013045.
PubMed
Abstract available
GS143, an inhibitor of E3 ligase beta-TrCP, reverses HIV-1 latency without
activating T cells via unconventional activation of NFkappaB.
PLoS Pathog. 2025;21:e1013018.
PubMed
Abstract available
Heat shock protein 90 is a chaperone regulator of HIV-1 latency.
PLoS Pathog. 2025;21:e1012524.
PubMed
Abstract available
Host ZAP activity correlates with the levels of CpG suppression in primate
lentiviruses.
Proc Natl Acad Sci U S A. 2025;122:e2419489122.
PubMed
Abstract available
Lenacapavir disrupts HIV-1 core integrity while stabilizing the capsid lattice.
Proc Natl Acad Sci U S A. 2025;122:e2420497122.
PubMed
Abstract available
Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related
hospitalisation amongst adult members of a private health insurance plan in South
Africa during the Delta and Omicron periods: A test-negative case-control study.
Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
PubMed
Abstract available
Prioritization and barriers of mpox vaccination uptake among gay, bisexual and
other men who have sex with men in Taiwan: 2023 HEART survey.
Vaccine. 2025;53:127059.
PubMed
Abstract available
Sociodemographic and health-related predictors of COVID-19 booster uptake among
fully vaccinated adults.
Vaccine. 2025;54:127048.
PubMed
Abstract available
Hepatitis B vaccination initiation and vaccination series completion: An in-depth
systematic evidence review, with meta-analysis of associations with individual
socioeconomic and health-related factors.
Vaccine. 2025;55:127051.
PubMed
Abstract available
Thank you for your interest in scientific medicine.